C4 Therapeutics Inc To Discuss CFT7455 Phase 1 Update Call Transcript
Hello, and welcome to the CFT7455 Phase 1 update investor call. (Operator Instructions)
Please note this event is being recorded. I would now like to hand the call to Courtney Solberg. Please go ahead.
Good afternoon, everyone, and thank you for joining our call to discuss Phase 1 dose escalation clinical data of CFT7455 for the potential treatment of relapse refractory multiple myeloma. We're making forward-looking statements today and Slide 2 contains our legal disclaimer on this matter.
Those presenting on today's call are Andrew Hirsch, our President and CEO; Steve Fisher, our Chief Scientific Officer; and Len Reyno, our Chief Medical Officer. We'll begin the opening remarks and then walk you through our preclinical and dose escalation clinical data of CFT7455 in relapse refractory multiple myeloma.
We will end today's call with a Q&A session. I will now turn the call over to Andrew Hirsch for some introductory remarks.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |